Sanofi (SNY) Set to Announce Quarterly Earnings on Thursday

Sanofi (NASDAQ:SNY) is set to announce its earnings results before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of $0.99 per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.94 by ($0.05). The firm had revenue of $11.76 billion during the quarter, compared to analysts’ expectations of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%. On average, analysts expect Sanofi to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Sanofi Trading Up 0.7 %

Sanofi stock opened at $46.11 on Thursday. The firm has a 50 day moving average of $47.55 and a 200 day moving average of $48.69. The firm has a market capitalization of $116.64 billion, a price-to-earnings ratio of 19.54, a P/E/G ratio of 1.73 and a beta of 0.61. Sanofi has a 12-month low of $42.63 and a 12-month high of $57.82. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 6th. Investors of record on Friday, May 10th will be issued a $1.478 dividend. This represents a yield of 2.98%. This is a positive change from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s dividend payout ratio is currently 62.29%.

Institutional Investors Weigh In On Sanofi

A number of institutional investors have recently added to or reduced their stakes in SNY. SRS Capital Advisors Inc. grew its holdings in Sanofi by 289.1% during the 1st quarter. SRS Capital Advisors Inc. now owns 463 shares of the company’s stock valued at $25,000 after buying an additional 344 shares in the last quarter. Fairfield Bush & CO. purchased a new stake in Sanofi during the 1st quarter valued at approximately $26,000. Eagle Bay Advisors LLC purchased a new stake in Sanofi during the 2nd quarter valued at approximately $28,000. O Dell Group LLC purchased a new position in shares of Sanofi in the fourth quarter valued at $40,000. Finally, First Manhattan Co. grew its holdings in shares of Sanofi by 42.7% in the fourth quarter. First Manhattan Co. now owns 999 shares of the company’s stock valued at $48,000 after purchasing an additional 299 shares in the last quarter. 10.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms recently issued reports on SNY. TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a report on Friday, February 9th. Morgan Stanley initiated coverage on shares of Sanofi in a report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 target price for the company. Finally, StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 27th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $55.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.